icon-facebook icon_twittericon-youtube
blog
ways_to_give
e_news
appointment
UAB CCC
UAB Study Reveals Novel Treatment Option for Triple-Negative Breast Cancer PDF Print E-mail

UAB researchers have discovered that a new combination of two existing cancer drugs can kill triple-negative breast cancer cells. Triple-negative breast cancer is a highly aggressive subtype of breast cancer that does not express receptors for estrogen, progesterone or human epidermal growth factor. Because most cancer drugs target these receptors, triple-negative breast cancer is difficult to treat.

Read more...
 
UAB Cancer Research Briefs PDF Print E-mail

October 25, 2012

UAB researcher receives grant to study cutting-edge therapy for pediatric brain cancer patients – Gregory Friedman, M.D., assistant professor in the UAB Division of Pediatric Hematology and Oncology, has been awarded a St. Baldrick’s Foundation Scholar grant of $330,000 for a period of three years to conduct research on medulloblastoma, the most common malignant brain tumor found in children. Friedman sees patients in The Alabama Center for Childhood Cancer and Blood Disorders at Children’s of Alabama.

Read more...
 
Cancer Center to Host Annual Community Report Event PDF Print E-mail

September 20, 2012

The UAB Comprehensive Cancer Center will present “Progress & Promise,” its annual report to the community, at 6 p.m. Monday, Oct. 8, 2012, at UAB’s Alys Stephens Center, 1200 10th Ave. South.

Read more...
 
UAB to Focus on Breast Cancer Awareness in October PDF Print E-mail

September 27, 2012

Each year, nearly 200,000 women are diagnosed with breast cancer and more than 40,000 will die. Breast cancer is the most common cancer among women and is the second leading cause of cancer death among women, after lung cancer. Although there have been significant strides in the fight against breast cancer, 1 in 8 women will get the disease, and continuous work still needs to be done to eliminate it as a public health problem.

Read more...
 
UAB Study Finds PARP Inhibitors May Have Use in HER2+ Breast Cancer PDF Print E-mail

September 17, 2012

New research from the University of Alabama at Birmingham shows that a class of drugs with clinical activity in familial breast and ovarian cancers may be useful in treating women with another, aggressive disease subtype known as HER2-positive breast cancer.

Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 6 of 30